Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Employee Benefits Update - June 1, 2001

Related Content

The Department of Labor Finalizes Changes to the QPAM Exemption – A Favored Management Tool Gets Less User-Friendly

Deadline Approaching for Reporting 2023 ISO Exercises and ESPP Transfers

Rushing to Chaos: The U.S. Department of Labor’s Well-Intentioned, Yet Unworkable Proposal to Redefine Fiduciary Investment Advice

ERISA Litigation Update

A Step Towards Guidance Instead of Regulation by Litigation in the ESOP Space

ERISA Litigation Update

Part III: What Primary Mitigation Strategies Exist for Companies with Double-Vest RSUs That May Be Expiring?

Part II: Why Do Private Companies Shift From Stock Options to Double-Vest RSUs?

Goodwin Represents the Underwriters in PACS Group $450 Million IPO

FASHIONPHILE Acquires Two Authenticators Inc. Business

Astera Labs Completes Upsized $774 Million Initial Public Offering

Fusion Pharmaceuticals To Be Acquired By AstraZeneca

John Hancock Gets Warm Reception in Foreign Tax Credit Appeal (Bloomberg Law)

John Hancock Clients Owed Tax Credit Perk, 11th Circ. Told (Law360)

Myrobalan Therapeutics Completes Series A Financing of $24 Million to Develop Potentially First-in-Class CNS Therapeutics with Restorative Potential

Harpoon Therapeutics To Be Acquired by Merck for $680 Million

ERISA & Executive Compensation